Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications
Journal of the American Academy of Child & Adolescent Psychiatry · 2026-01
DOI: 10.1016/j.jaac.2026.01.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Child & Adolescent Psychiatry, 2026-01. Verfasst von Le Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen University, Shenzhen, Guangdong, China; Karolinska Institute, Stockholm, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Foundation for Suicide Prevention, Swedish Research Council.
Abstract (Originalsprache)
OBJECTIVE: Second-generation antipsychotic (SGA) treatment has increased in youth globally. However, the effects of these agents on real-world outcomes are largely unknown, especially for non-approved indications. METHOD: This study included a national cohort of incident SGA recipients 7 to 17 years of age in Sweden from 2007 to 2020. Youth were followed from 1 year before SGA initiation through up to 1 year afterward, and in recurrent treatment analyses, up to 13 years after initiation. Within-individual comparisons were used to examine the risk of psychiatric hospitalization, self-harm, accidental injury, and violent crime before and after treatment. RESULTS: The study included 21,306 SGA initiators (53.1% male; median age 14.8 years at baseline). Indications included psychosis-related disorders (1,966 [9.2%]), autism spectrum disorders (5,140 [24.1%]), depression/other mood disorders (3,669 [17.2%]), intellectual disability (987 [4.6%]), and attention-deficit/hyperactivity disorder (2,992 [14.0%]). Within a year of initiation, 5,604 (26.3%) experienced psychiatric hospitalization, 1,749 (8.2%) self-harm, 954 (13.6% of those ≥16 years of age) violent crime, and 3,134 (14.7%) accidental injury. Risks were generally elevated immediately before SGA initiation and decreased across subsequent treatment without fully returning to baseline, although there was variation across indications. For example, psychiatric hospitalization and self-harm displayed larger pre-initiation elevations and subsequent decreases for youth with psychosis-related disorders (eg, psychiatric hospitalization: pre-initiation odds ratio [ORpre] = 11.30 [95% CI, 9.84-12.97]; ORpost = 2.59 [95% CI = 2.21-3.02]). Conversely, youth with neurodevelopmental disorders demonstrated greater decreases in violent crime (eg, attention-deficit/hyperactivity disorder: ORpre = 1.66 [95% CI, 1.23-2.26]; ORpost = 1.26 [95% CI, 0.94-1.70]). Accidental injury risk did not statistically significantly differ (eg, ASD: ORpost = 0.90 [95% CI, 0.77-1.07]). CONCLUSION: After having escalated before initiation, risk of psychiatric hospitalization, self-harm, and violent crime decreased during SGA treatment without fully returning to baseline. There was little evidence of associations with accidental injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shenzhen University, Shenzhen, Guangdong, China; Karolinska Institute, Stockholm, Sweden.
- Indiana University, Bloomington, Indiana.
- Karolinska Institute, Stockholm, Sweden; Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
- Karolinska Institute, Stockholm, Sweden; University of Bergen, Bergen, Norway; Aarhus University, Aarhus, Denmark.
- Karolinska Institute, Stockholm, Sweden.
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Förderung
- American Foundation for Suicide Prevention
- Swedish Research Council
Zitieren
APA
Zhang, L., Quinn, P. D., Bjureberg, J., Hellner, C., Sepe-Forrest, L., Brikell, I., Kuja-Halkola, R., Froehlich, T. E., D'Onofrio, B. M., & Chang, Z. (2026). Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2026.01.009
Vancouver
Zhang L, Quinn PD, Bjureberg J, Hellner C, Sepe-Forrest L, Brikell I, et al. Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications. Journal of the American Academy of Child & Adolescent Psychiatry. 2026. doi:10.1016/j.jaac.2026.01.009
BibTeX
@article{Zhang2026,
author = {Zhang, Le and Quinn, Patrick D and Bjureberg, Johan and Hellner, Clara and Sepe-Forrest, Linnea and Brikell, Isabell and Kuja-Halkola, Ralf and Froehlich, Tanya E and D'Onofrio, Brian M and Chang, Zheng},
title = {Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label Indications},
journal = {Journal of the American Academy of Child & Adolescent Psychiatry},
year = {2026},
doi = {10.1016/j.jaac.2026.01.009}
}
EUVIMED